Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Other(2)

Detailed Status

Suspended2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

suspended2100%

Recent Activity

0 active trials
Showing 2 of 2
suspendedphase_1

A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours

NCT00459823
suspendedphase_1

A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

NCT00499499

Clinical Trials (2)

Showing 2 of 2 trials
NCT00459823Phase 1

A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours

Suspended
NCT00499499Phase 1

A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

Suspended

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2